menu
    • menu
    [{"orgOrder":0,"company":"Chase Therapeutics","sponsor":"Chinalink Asia Holdings","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Pramipexole DiHCl","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Chase Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Chase Therapeutics \/ Chinalink Asia Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Chase Therapeutics \/ Chinalink Asia Holdings"},{"orgOrder":0,"company":"Chase Therapeutics","sponsor":"Alto Neuroscience","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Chase Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.070000000000000007,"dosageForm":"Oral Tablet","sponsorNew":"Chase Therapeutics \/ Alto Neuroscience","highestDevelopmentStatusID":"8","companyTruncated":"Chase Therapeutics \/ Alto Neuroscience"}]

    Find Clinical Drug Pipeline Developments & Deals by Chase Therapeutics

    Menu

    Chase Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chase Therapeutics

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed

                            Chase Therapeutics

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pramipexole Dihydrochloride,Ondansetron

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Alto Neuroscience

                            Deal Size : $73.2 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product

                            Details : Alto gains a portfolio of potentially best-in-class dopamine agonist, including ALTO-207, a fixed-dose combination of pramipexole and ondansetron, for treatment resistant depression.

                            Product Name : ALTO-207

                            Product Type : Other Small Molecule

                            Upfront Cash : $1.7 million

                            June 03, 2025

                            Lead Product(s) : Pramipexole Dihydrochloride,Ondansetron

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Alto Neuroscience

                            Deal Size : $73.2 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chase Therapeutics

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed

                            Chase Therapeutics

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pramipexole DiHCl

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Chinalink Asia Holdings

                            Deal Size : $20.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Chase Therapeutics Announces $20 Million Series B Financing to Advance Clinical Trials in Parkinson’s Diseas...

                            Details : The proceeds will support Phase 3 pivotal trials for CTC-501 for the treatment of Major Depressive Disorder (MDD) and CTC-413 for the treatment of Parkinson’s Disease (PD) as well as completion of the development and validation of a diagnostic product ...

                            Product Name : CTC-501

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 20, 2021

                            Lead Product(s) : Pramipexole DiHCl

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Chinalink Asia Holdings

                            Deal Size : $20.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth